TSHR fusion protein as well as preparation method and application thereof
By fusing TSHR with the variable lymphocyte receptor (VLR) gene sequence of lamprey, the problems of insufficient stability and purity of TSHR protein were solved, and a high-expression and high-purity TSHR fusion protein was achieved, providing an effective detection method and large-scale production capacity for the diagnosis of thyroid diseases.
Patent Information
- Application Number
- CN202310507126.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-08
- Publication Date
- 2024-11-08
AI Technical Summary
In existing technologies, the stability, purity, and expression level of TSHR proteins are insufficient, resulting in poor sensitivity and specificity in clinical testing and making large-scale production difficult.
A modified TSHR fusion protein was constructed by fusing the TSHR gene sequence with the lamprey variable lymphocyte receptor (VLR) gene sequence. The expression system was optimized and the protein was purified to improve the stability and purity of the protein and enhance its binding ability to thyroid-stimulating antibody (TSAb).
It significantly improved the expression level and purity of TSHR protein, provided a highly sensitive detection method, offered a theoretical basis for the diagnosis of thyroid diseases, and supported large-scale production.
Smart Images

Figure CN118910106A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of bioengineering technology, and in particular to a TSHR (thyroid stimulating hormone receptor) fusion protein and a preparation method and application thereof. Specifically, the TSHR fusion protein is obtained by fusion expression of the gene sequence of TSHR with the gene sequence of lamprey variable lymphocyte receptor (VLR). Background Art
[0002] The thyrotropin receptor (TSHR, https: / / www.uniprot.org / uniprotkb / P16473 / entry) exists on the membrane of thyroid follicular cells (TECs). It binds to thyroid stimulating hormone (TSH) and regulates the growth, differentiation, synthesis, and release of thyroid hormones by TECs. Based on the influence of environmental and genetic factors, the body's immune function is abnormal, TSHR becomes an autoantigen and produces autoantibodies TRAb, leading to autoimmune thyroid disease (AITD). AITD is an organ-specific autoimmune disease, including Graves' disease (GD), thyroiditis, and primary hypothyroidism. GD is the most common type of thyrotoxicosis, TSHR is the most important pathogenic antigen of GD, and TRAb is closely related to the occurrence of GD. TRAb is a heterogeneous polyclonal antibody, of which there are three main types: (1) thyroid stimulating antibodies (TSAb), which mainly activate the adenylate cyclase-cyclic adenosine monophosphate (cAMP) pathway, stimulate the growth of thyroid follicles and increase the secretion of thyroid hormones, leading to hyperthyroidism; TSAb is the main cause of GD and plays an important role in the occurrence and development of GD; (2) thyroid stimulating blocking antibodies (TSBAb), which can block the excitatory effect of TSH on the thyroid gland, causing hypothyroidism; (3) neutral autoantibodies, which neither activate TSHR nor block the activation of TSHR by TSH after binding to TSHR.
[0003] A large number of studies have shown that the epitope of thyroid stimulating antibodies (TSAb) mainly exists upstream of the amino acid residue at position 289 of TSHR. Therefore, it is an effective means to recombinantly express this segment of protein to detect thyroid stimulating antibodies in vivo. TSHR belongs to G protein-coupled receptors. It is very difficult to recombinantly express and purify it in vitro. It is difficult to obtain soluble TSHR protein in Escherichia coli and E. coli. Therefore, the TSHR currently used in clinical practice is often a human or pig thyroid cell membrane extract, or a lysate expressing the full-length TSHR protein. Both of these have insufficient protein stability and purity, which will cause clinical sensitivity, specificity and reagent batch differences. Ulrich of Germany (reference CN201580040213.X) fused the amino acid sequence of TSHR with HSA and developed a kit with this as the raw material. The stability and sensitivity have been greatly improved, but this scheme has the problem that the expression amount is too small and the protein cannot be produced on a large scale. Sanofi Pasteur studied the polymerisation of recombinant proteins by fusion to sequences from lampreys (CN107108755B), but did not solve the following problems: improving the stability and purity of the target protein while increasing the expression level, nor did it involve the expression of TSHR fusion proteins. Summary of the invention
[0004] In order to overcome at least one problem existing in the prior art, the present invention significantly increases the expression level of TSHR by fusing the gene sequence of thyroid stimulating hormone receptor (TSHR) (TSHR agonist epitope gene sequence) with the receptor protein lamprey variable lymphocyte receptor (VLR).
[0005] To achieve the above object, the present invention adopts the following technical solution:
[0006] The first aspect of the present invention is to provide a modified TSHR gene sequence, which comprises the gene sequence of TSHR and the gene sequence of lamprey variable lymphocyte receptor.
[0007] Furthermore, the gene sequence of the TSHR comprises a partial gene sequence (including its full-length sequence) in the sequence shown in SEQ ID No.1 (encoding protein amino acids 1-413 (full length 764aa)) or a nucleotide sequence having at least 85% homology with the partial gene sequence. The amino acid sequence encoded by the above partial gene sequence can bind to thyroid stimulating antibodies (TSAb). The above TSHR amino acids 1-413 are the receptor extracellular domain (ECD) of TSHR.
[0008] Furthermore, the gene sequence of TSHR is one of the following sequences: the sequence shown in SEQ ID No.2 (encoding protein amino acids 1-260) or a nucleotide sequence having at least 85% homology thereto, the sequence shown in SEQ ID No.3 (encoding protein amino acids 1-289) or a nucleotide sequence having at least 85% homology thereto.
[0009] Furthermore, the gene sequence of the lamprey variable lymphocyte receptor includes the sequence shown in SEQ ID No. 4 or a nucleotide sequence having at least 85% homology thereto.
[0010] Furthermore, an exogenous sequence is inserted between the gene sequence of TSHR and the gene sequence of lamprey variable lymphocyte receptor, and the exogenous sequence includes a nucleic acid sequence encoding a linker sequence and / or a protease cleavage site sequence.
[0011] It is understood that the above-mentioned linker can be a short peptide sequence or another suitable covalent connection between protein domains. Preferably, the linker is a short peptide sequence. Preferably, the peptide linker is composed of flexible residues such as glycine (G) and serine (S), so that adjacent protein domains can move freely relative to each other. Preferably, the linker is at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or at least 15 amino acid residues in length. It is understood that any possible linker can be used for the purpose of the present invention. For example, the linker can be a G6S9 (6 glycines followed by 9 serines) linker, a G8 linker, a G4S3 linker, a (GGGGS) 3-linker, a (EAAAK) 3-linker, etc.
[0012] It is understandable that the above-mentioned protease cleavage site is a specific amino acid sequence that can be recognized by the protease, and the above-mentioned cleavage site can be any suitable enzyme cleavage site conventionally used in the art, such as a Thrombin or TEV cleavage site.
[0013] The second aspect of the present invention is to provide a TSHR fusion protein, which is encoded by any modified TSHR gene sequence described in the first aspect of the present invention.
[0014] Further, the TSHR fusion protein comprises the amino acid sequence of TSHR and the amino acid sequence of lamprey variable lymphocyte receptor, and the amino acid sequence of TSHR comprises a partial amino acid sequence (including the full-length sequence) in the sequence shown in SEQ ID No.5 (1-413aa) or an amino acid sequence having at least 85% homology with the amino acid gene sequence. The above partial amino acid sequence and its homologous sequence can bind to thyroid stimulating antibodies (TSAb). Specifically, the amino acid sequence of TSHR can be 1-260, 1-289, 1-413, 22-91, 246-260, 260-363, 380-413, 21-260, 21-413, 21-330, 261-330, etc. It is understandable that other suitable TSHR epitopes that can bind to relevant antibodies or fragments thereof can be adopted.
[0015] Furthermore, the amino acid sequence having at least 85% homology to the amino acid sequence of TSHR is mutated on the basis of its amino acid sequence, for example, in the sequence shown in SEQ ID No.5 (1-413aa), its subsequent mutation sites include at least one of: R112P, D143P, D151E, V169R, I253R. The purpose of the above amino acid site mutation is to further improve the stability of protein expression and its yield.
[0016] Furthermore, the amino acid sequence of the TSHR is selected from one of the following sequences: an amino acid sequence (1-260aa) as shown in SEQ ID No.6 or an amino acid sequence having at least 85% homology thereto and the amino acid sequence binds to TSAb, an amino acid sequence (1-289aa) as shown in SEQ ID No.7 or an amino acid sequence having at least 85% homology thereto and the amino acid sequence binds to TSAb.
[0017] Furthermore, the amino acid sequence of the lamprey variable lymphocyte receptor includes the amino acid sequence shown in SEQ ID No. 8 or an amino acid sequence having at least 85% homology thereto.
[0018] Furthermore, the amino acid sequence having at least 85% homology to the amino acid sequence of lamprey variable lymphocyte receptor is a sequence in which certain positions are mutated. Specifically, the amino acid sequence shown in SEQ ID No. 8 is selected from the 88th to 153rd amino acids in the original amino acid sequence, and the following mutation is made at position 153: T153L. The above-mentioned VLR fragments or their mutations are all for the purpose of increasing the protein expression by enhancing the stability of the protein structure. Therefore, it can be understood that the VLR fragments and their mutations that can achieve the above-mentioned functions can be used to construct TSHR fusion proteins.
[0019] The specific sequences involved are shown in the following table:
[0020] Table 1 – Sequence information of TSHR
[0021]
[0022]
[0023]
[0024]
[0025] The third aspect of the present invention is to provide a biological material related to any of the modified TSHR gene sequences described in the first aspect of the present invention or to any of the TSHR fusion proteins described in the first aspect of the present invention, which is a recombinant vector or a recombinant cell line containing the modified TSHR gene sequence. The recombinant vector or recombinant cell line can express the TSHR fusion protein.
[0026] Furthermore, the recombinant vector is a eukaryotic cell expression vector.
[0027] Furthermore, the eukaryotic cell expression vector includes a mammalian cell expression vector, and the mammalian cell expression vector includes a pCDNA3.1 plasmid and a pCMV plasmid.
[0028] Furthermore, the recombinant cell line is a eukaryotic cell.
[0029] Furthermore, the eukaryotic cells include mammalian cells, and the mammalian cells include HEK293 cells (such as Expi293 cells) and CHO cells.
[0030] It is understandable that the above-mentioned eukaryotic cell expression vectors and eukaryotic cells can be replaced by vectors and cells suitable for use in the art.
[0031] The fourth aspect of the present invention is to provide an application of the modified TSHR gene sequence described in any of the first aspect of the present invention, or the TSHR fusion protein described in any of the second aspect of the present invention, or the biomaterial described in any of the third aspect of the present invention, which is selected from at least one of the following applications: application in the preparation of TSHR, application in the detection of TSAb for non-diagnostic purposes, application in the preparation of products for detecting TSAb, and application in the preparation of products for diagnosing thyroid disease.
[0032] Furthermore, the thyroid disease includes hyperthyroidism, thyrotoxicosis, Graves' disease, etc.
[0033] The fifth aspect of the present invention is to provide a method for preparing a TSHR fusion protein, which comprises the steps of: preparing the TSHR fusion protein by expressing any of the modified TSHR gene sequences described in the first aspect of the present invention, wherein the modified TSHR gene sequence comprises the gene sequence of TSHR and the gene sequence of lamprey variable lymphocyte receptor.
[0034] Furthermore, in the above method for preparing TSHR fusion protein, the gene sequence of TSHR and the gene sequence of lamprey variable lymphocyte receptor are constructed into a mammalian cell expression vector and transiently or stably transfected into eukaryotic cells.
[0035] Furthermore, the mammalian cell expression vector includes pCDNA3.1 plasmid and pCMV plasmid.
[0036] Furthermore, the eukaryotic cells include mammalian cells, and the mammalian cells include HEK293 cells (such as Expi293 cells) and CHO cells.
[0037] Furthermore, when the gene sequence is constructed into a mammalian cell expression vector, a Kozac sequence is added before the start codon ATG, a His tag is added to the C-terminus, and an exogenous signal peptide is added. The exogenous signal peptide can be a signal peptide conventionally used in the art, and can be detected by mammalian cell expression. In a specific embodiment, a signal peptide with a good protein secretion expression effect of the TSHR fusion protein sequence is screened.
[0038] Furthermore, in the above method for preparing TSHR fusion protein, a purification step of TSHR fusion protein is also included, including: transient transfection of Expi293 cells in a shake flask, harvesting the secretion supernatant, hanging the column with a nickel-loaded IMAC pre-loaded column, washing and eluting with a buffer, dialyzing the eluted protein into a buffer, concentrating with a concentrator to obtain a purified TSHR fusion protein.
[0039] Compared with the prior art, the present invention adopts the above technical solution to have the following beneficial effects:
[0040] The present invention effectively ensures the stability and purity of the target protein and significantly improves its expression level by constructing a TSHR recombinant gene sequence, optimizing the expression system of its fusion protein and the protein purification method; at the same time, the present invention experimentally verifies that the TSHR fusion protein can effectively distinguish thyroid stimulating antibodies, which provides a basis for the large-scale production of TSHR protein and a theoretical basis for the diagnosis of related thyroid diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] The drawings described herein are used to provide a further understanding of the present invention and constitute a part of the present invention. The exemplary embodiments of the present invention and their descriptions are only used to explain the present invention and do not constitute an improper limitation of the present invention. In the drawings:
[0042] Figure 1 This is a schematic diagram of the protein expression level of the fusion expression of the gene sequence of TSHR and lamprey variable lymphocyte receptor (TSHR1-260 VLR) in one embodiment of the present invention;
[0043] Figure 2 This is a schematic diagram of the protein expression amount (TSHR1-289VLR) expressed by fusion of the gene sequence of TSHR and lamprey variable lymphocyte receptor in one embodiment of the present invention;
[0044] Figure 3 This is a schematic diagram of the protein expression level using the fusion expression of the THSR sequence and the human albumin gene in a comparative experiment of the present invention. DETAILED DESCRIPTION
[0045] The following will be combined with the accompanying drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in the field without creative work belong to the scope of protection of the present invention. The experimental methods without specific conditions in the following embodiments are usually measured according to national standards. The experimental materials without the source indicated in the following embodiments are all commercially available raw materials. The equipment used in each step in the following embodiments is conventional equipment. If there is no corresponding national standard, it is carried out according to the general international standards, conventional conditions, or according to the conditions recommended by the manufacturer. Unless otherwise specified, all parts are weight parts and all percentages are mass percentages. Unless otherwise defined or specified, all professional and scientific terms used in the present invention have the same meaning as those familiar to those skilled in the art. In addition, any method and material similar or equal to the recorded content can be applied to the method of the present invention.
[0046] In a specific embodiment of the present invention, the modified TSHR gene sequence includes the gene sequence of TSHR and the gene sequence of lamprey variable lymphocyte receptor, the gene sequence of TSHR includes the partial gene sequence (including its full-length sequence) in the sequence shown as SEQ ID No.1 (encoding protein 1-413 amino acids (full length 764aa)) or a nucleotide sequence with at least 85% homology to the partial gene sequence, and the gene sequence of lamprey variable lymphocyte receptor includes SEQ ID No.4 or a nucleotide sequence with at least 85% homology thereto. The amino acid sequence encoded by the above partial gene sequence can bind to thyroid stimulating antibodies (TSAb). The TSHR fusion protein comprises the amino acid sequence of TSHR and the amino acid sequence of lamprey variable lymphocyte receptor, wherein the amino acid sequence of TSHR is a partial amino acid sequence (including the full-length sequence) in the sequence shown in SEQ ID No.5 (1-413aa) or an amino acid sequence having at least 85% homology with the amino acid gene sequence, and the amino acid sequence of lamprey variable lymphocyte receptor comprises SEQ ID No.8 or an amino acid sequence having at least 85% homology therewith. The above homology can be specifically 85%, 90%, 95%, etc.
[0047] The term "homology" refers to the number of exactly matched nucleotides / amino acids between two sequences aligned in a sequence alignment (expressed as a percentage), which is calculated using the number of identical positions divided by the number of equivalent positions in the larger sequence or excluding overhangs in the shortest sequence, wherein internal gaps are counted as equivalent positions; in certain embodiments, any reference to sequence homology expressed herein may be replaced by sequence similarity or sequence identity. The term "mutation" refers to the replacement of one amino acid or nucleotide by another amino acid or nucleotide, and the mutation also includes mutations obtained by known synthetic techniques, for example, mutations obtained by using traditional peptide synthesis to affect the synthesis of a desired polypeptide sequence, wherein the synthesized sequence includes the replacement of a desired amino acid with another amino acid.
[0048] It should be noted that, in the absence of conflict, the embodiments of the present invention and the features in the embodiments can be combined with each other. The present invention is further described below in conjunction with the drawings and specific embodiments, but is not intended to be a limitation of the present invention.
[0049] The experimental materials used in the following examples include:
[0050] Expression cells: Expi293 Thermo Fisher Scientific;
[0051] Culture medium: Optima CD05;
[0052] Nickel-loaded IMAC resin: Kingsray Biotech;
[0053] Protein A280 concentration determination Nanodrop: Aosheng Nano-300;
[0054] Imidazole, phosphate, Tris-base, NaCl and other chemical reagents: Shanghai Bioengineering;
[0055] SDS-page gel electrophoresis system: Tanon Shanghai Tianneng Technology Co., Ltd.
[0056] Example 1- Preparation of TSHR-VLR fusion protein and protein expression detection
[0057] In this example, two TSHR-VLR fusion proteins were prepared: TSHR1-260 VLR fusion protein (TSHR gene sequence is shown in SEQ ID No.2, VLR gene sequence is shown in SEQ ID No.4; TSHR amino acid sequence is shown in SEQ ID No.6, VLR amino acid sequence is shown in SEQ ID No.8) and TSHR1-289 VLR fusion protein (TSHR gene sequence is shown in SEQ ID No.3, VLR gene sequence is shown in SEQ ID No.4; TSHR amino acid sequence is shown in SEQ ID No.7, VLR amino acid sequence is shown in SEQ ID No.8).
[0058] (1) Synthesis of fusion protein gene sequence
[0059] The gene sequences of the above-mentioned TSHR1-260 VLR fusion protein and TSHR1-289 VLR fusion protein were synthesized by General Biosystems (Anhui) Co., Ltd. During the synthesis process, a Kozac sequence was added in front of the start codon ATG, and a His tag was added to the C-terminus to construct them into the pCDNA3.1 mammalian cell expression vector (other expression vectors such as pCMV can also be selected as an alternative), and the sequencing was correct.
[0060] Signal peptides with good secretion and expression effects on TSHR sequence fusion protein 1 and TSHR fusion protein sequence 2 proteins can be screened out through mammalian cell expression detection, such as GAUSSIA LUCIFERASE SP: MGVKVLFALICIAVAEA (ATGGGAGTCAAAGTTCTGTTTGCCCTGATCTGCATCGCTGT GGCCGAGGCC); murine IgG kappa V SP: MDMRVPAQLLGLLLLWFSGVLG (ATGG ATATGAGAGTTCCTGCTCAATTGCTGGGGTTGCTCTTGCTCTGGTTCAGTGGGGTGTT GGGG), but the exogenous signal peptide is not limited to the preferred signal peptide disclosed in this embodiment.
[0061] (2) Transient transfection of mammalian cells Expi293 and protein expression detection
[0062] Expi 293 cell transient transfection method: refer to the protocol provided by Opma. Expi 293 is cultured in 293 medium. After the density grows to 1 times 106, a mixture of PEI and plasmid is added. The ratio of cells to plasmid is generally 1 microgram of plasmid per milliliter of cells, and the ratio of PEI to plasmid is generally 3 to 1. After mixing, place it in a 37°C shaker for culture. Generally, 293pro FEED is added on the second and fifth days. On the seventh day, the cell supernatant is harvested by centrifugation for protein purification and identification. The protein purification steps include: transient transfection of Expi293 cells in a shake flask, harvesting 1L of secretion supernatant, hanging the column with a nickel-loaded IMAC pre-packed column with a 5ml column volume, and the equilibrium buffer is 20mM PB, 500mM NaCl, pH7.4; washing 5 column volumes with 20mMPB, 500mM NaCl, 20mM imidazole, pH7.4 buffer, and washing 5 column volumes with 20mM PB, 500mM NaCl, 50mM imidazole, pH7.4 buffer. Elution with 20mM PB, 500mM NaCl, 500mM imidazole, pH7.4 buffer. The eluted protein was dialyzed into PBS, pH7.4 buffer, and concentrated with a 3kDa cutoff concentrator. The expression results of the obtained TSHR1-289 VLR fusion protein and TSHR1-289VLR fusion protein are shown as follows, respectively. Figure 1 and Figure 2 shown.
[0063] The above results show that the expression level of TSHR1-260 VLR fusion protein in 293 cells is about 5 mg / L, and the expression level of TSHR1-289 VLR is about 3 mg / L.
[0064] (3) Steady-state transfection of mammalian CHO cells and protein expression detection
[0065] CHO stable transformation method: The gene is transferred into CHO cells, and the cells are screened using the corresponding screening marker antibiotics (such as puromycin) or GS nutritional deficiency marker screening method. The stable cells obtained become CHO stable cell lines. The results show that the current expression levels of TSHR1-260 VLR fusion protein and TSHR1-289 VLR fusion protein in CHO stable cells are about 10 times higher than those of transient expression. Specifically, the protein expression level is about 25 mg / L under non-feed conditions, and can be further increased by 10-20 times (about several hundred milligrams) under feed conditions.
[0066] The establishment of the above-mentioned CHO stable expression strain further improved the protein expression level, which provided a basis for subsequent large-scale production.
[0067] (4) Comparative experimental group - TSHR 1-260HSA fusion protein expression
[0068] The comparative experimental group used the THSR1-260 sequence and the human albumin gene for fusion expression. The gene sequence and amino acid sequence are shown in Table 1 above. The protein transient expression steps were the same as the above step (2). The results showed that the protein expression level was very low, 100 micrograms per liter, and it was not possible to do large-scale production. Figure 3 Schematic diagram of supernatant expression detected by His antibody.
[0069] From the above comparison, it can be seen that the TSHR protein expression levels obtained by the transient and stable expression systems of TSHR-VLR fusion protein constructed in this example are much higher than those of the expression systems in the prior art.
[0070] Example 2 - Application of TSHR-VLR fusion protein in detecting thyroid stimulating antibodies (TSAb)
[0071] The application of the prepared TSHR1-260 VLR fusion protein in detecting thyroid stimulating antibodies (TSAb) in this embodiment includes the following steps:
[0072] Take TSHR1-260VLR fusion protein, dilute it with PBS to 1ug / mL, add it to the ELISA plate at 100ng / well, coat it overnight, and block it with 5% skim milk the next day. The positive patient serum is 26 positive cases of hyperthyroidism, and the negative control is normal human serum. Dilute it at 1:10000, add 100 microliters to each well, place it at 37℃ for 1 hour, wash it with PBST, add the secondary antibody, which is HRP-labeled anti-human IgG, place it at 37℃ for 1 hour, wash it with PBST, and add the colorimetric agent. The results are shown in the following table:
[0073] sample OD value sample OD value Positive 1 2.6127 Positive 19 1.9924 Positive 2 2.6664 Positive 20 2.1225 Positive 3 2.319 Positive 21 1.7675 Positive 4 2.178 Positive 22 2.078 Positive 5 2.6551 Positive 23 2.1604 Positive 6 2.8396 Positive 24 1.3316 Positive 7 2.1322 Positive 25 2.4754 Positive 8 2.6839 Positive 26 2.4863 Positive 9 2.3828 Negative 1 0.1877 Positive 10 2.3404 Negative 2 0.1420 Positive 11 2.1670 Negative 3 0.1434 Positive 12 2.1591 Negative 4 0.1910 Positive 13 2.1390 Negative 5 0.1549 Positive 14 1.7760 Negative 6 0.1200 Positive 15 2.5886 Negative 7 0.1602 Positive 16 2.6077 Negative 8 0.2583 Positive 17 1.6335 Negative 9 0.1172 Positive 18 2.5079 Negative 10 0.1432
[0074] The above results show that the TSHR1-260VLR fusion protein has a strong discrimination in detecting thyroid stimulating antibodies, which indicates that the TSHR-VLR fusion protein can be used as an antigen for detecting thyroid stimulating antibodies.
[0075] It can be seen from the above embodiments that the present invention screened and obtained a VLR sequence for the first time, which can be used to construct a stably expressed TSHR-VLR fusion protein with a TSHR sequence. The method adopted by the present invention can prepare a TSHR fusion protein with high protein expression and high purity, which can effectively distinguish thyroid stimulating antibodies, and lay a certain foundation for the large-scale production of TSHR protein and the diagnosis of thyroid disease.
[0076] The specific embodiments of the present invention are described in detail above, but they are only examples, and the present invention is not limited to the specific embodiments described above. For those skilled in the art, any equivalent modifications and substitutions made to the present invention are also within the scope of the present invention. Therefore, the equalization changes and modifications made without departing from the spirit and scope of the present invention should be included in the scope of the present invention.
Claims
1. A modified TSHR gene sequence, characterized in that: The modified TSHR gene sequence comprises the gene sequence of TSHR and the gene sequence of lamprey variable lymphocyte receptor.
2. A modified TSHR gene sequence according to claim 1, characterized in that: The TSHR gene sequence comprises one of the following sequences: a sequence as shown in SEQ ID No.1 or a nucleotide sequence having at least 85% homology thereto, a sequence as shown in SEQ ID No.2 or a nucleotide sequence having at least 85% homology thereto, a sequence as shown in SEQ ID No.3 or a nucleotide sequence having at least 85% homology thereto; And / or, the gene sequence of the lamprey variable lymphocyte receptor includes the sequence shown in SEQ ID No. 4 or a nucleotide sequence having at least 85% homology thereto.
3. A modified TSHR gene sequence according to claim 1, characterized in that: An exogenous sequence is inserted between the gene sequence of TSHR and the gene sequence of lamprey variable lymphocyte receptor, and the exogenous sequence includes a nucleic acid sequence encoding a linker sequence and / or a protease cleavage site sequence.
4. A TSHR fusion protein, characterized in that The amino acid sequence of the TSHR fusion protein is encoded by the modified TSHR gene sequence according to any one of claims 1 to 3.
5. A TSHR fusion protein according to claim 4, characterized in that: The TSHR fusion protein comprises an amino acid sequence of TSHR and an amino acid sequence of lamprey variable lymphocyte receptor, wherein the amino acid sequence of TSHR comprises one of the following sequences: an amino acid sequence as shown in SEQ ID No.5 or an amino acid sequence having at least 85% homology thereto and the amino acid sequence binds to TSAb, an amino acid sequence as shown in SEQ ID No.6 or an amino acid sequence having at least 85% homology thereto and the amino acid sequence binds to TSAb, an amino acid sequence as shown in SEQ ID No.7 or an amino acid sequence having at least 85% homology thereto and the amino acid sequence binds to TSAb; And / or, the amino acid sequence of the lamprey variable lymphocyte receptor comprises the amino acid sequence shown in SEQ ID No. 8 or an amino acid sequence having at least 85% homology thereto.
6. A biological material related to the modified TSHR gene sequence according to any one of claims 1 to 3 or to the TSHR fusion protein sequence according to any one of claims 4 to 5, characterized in that: The biological material comprises a recombinant vector and a recombinant cell line containing the modified TSHR gene sequence according to any one of claims 1 to 3.
7. The biomaterial according to claim 6, characterized in that The recombinant vector is a eukaryotic cell expression vector, which includes a mammalian cell expression vector, and the mammalian cell expression vector includes a pCDNA3.1 plasmid and a pCMV plasmid; And / or, the recombinant cell line is a eukaryotic cell, and the eukaryotic cell includes a mammalian cell, and the mammalian cell includes a HEK293 cell and a CHO cell.
8. A use of the modified TSHR gene sequence according to any one of claims 1 to 3, the TSHR fusion protein according to any one of claims 4 to 5, or the biomaterial according to any one of claims 6 to 7, characterized in that: The application is selected from at least one of the following applications: application in the preparation of TSHR, application in the detection of TSAb for non-diagnostic purposes, application in the preparation of products for detecting TSAb, and application in the preparation of products for diagnosing thyroid disease.
9. A method for preparing a TSHR fusion protein, characterized in that: The method comprises the steps of: preparing the TSHR fusion protein by expressing the modified TSHR gene sequence according to any one of claims 1 to 3, wherein the modified TSHR gene sequence comprises the gene sequence of TSHR and the gene sequence of lamprey variable lymphocyte receptor.
10. The method for preparing TSHR fusion protein according to claim 9, characterized in that: The gene sequence of the TSHR and the gene sequence of the lamprey variable lymphocyte receptor are constructed into a mammalian cell expression vector and transiently or stably transfected into eukaryotic cells.
Citation Information
Cited By
Expression vector, signal peptide and method for highly expressing human TGF-beta3
CN121780615A
